ValuEngine Lowers Endologix (ELGX) to Strong Sell
ValuEngine cut shares of Endologix (NASDAQ:ELGX) from a sell rating to a strong sell rating in a research report report published on Sunday morning.
ELGX has been the subject of several other research reports. Royal Bank of Canada lowered their target price on shares of Endologix from $5.00 to $4.00 and set a sector perform rating for the company in a research note on Wednesday, November 8th. Stifel Nicolaus set a $6.00 price target on shares of Endologix and gave the company a hold rating in a report on Friday, October 6th. BidaskClub cut shares of Endologix from a buy rating to a hold rating in a report on Friday, December 15th. Canaccord Genuity reiterated a hold rating and issued a $5.00 price target on shares of Endologix in a report on Wednesday, September 27th. Finally, Piper Jaffray Companies reiterated an overweight rating on shares of Endologix in a report on Tuesday, December 12th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $5.41.
Shares of Endologix (NASDAQ ELGX) traded down $0.18 during trading hours on Friday, reaching $5.17. 2,297,200 shares of the company’s stock traded hands, compared to its average volume of 1,362,650. Endologix has a 1 year low of $4.08 and a 1 year high of $7.66. The company has a debt-to-equity ratio of 2.61, a current ratio of 2.90 and a quick ratio of 2.11. The company has a market capitalization of $446.48, a P/E ratio of -5.56 and a beta of 0.72.
Several institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers boosted its holdings in shares of Endologix by 0.4% in the second quarter. Rhumbline Advisers now owns 95,581 shares of the medical instruments supplier’s stock valued at $465,000 after buying an additional 381 shares during the period. Kopp Investment Advisors LLC boosted its holdings in Endologix by 11.5% during the second quarter. Kopp Investment Advisors LLC now owns 21,950 shares of the medical instruments supplier’s stock worth $107,000 after purchasing an additional 2,270 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Endologix by 4.3% during the second quarter. The Manufacturers Life Insurance Company now owns 66,890 shares of the medical instruments supplier’s stock worth $325,000 after purchasing an additional 2,738 shares during the last quarter. Voya Investment Management LLC boosted its holdings in Endologix by 16.4% during the second quarter. Voya Investment Management LLC now owns 38,910 shares of the medical instruments supplier’s stock worth $189,000 after purchasing an additional 5,471 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in Endologix by 11.5% during the second quarter. Alliancebernstein L.P. now owns 108,757 shares of the medical instruments supplier’s stock worth $529,000 after purchasing an additional 11,200 shares during the last quarter.
COPYRIGHT VIOLATION NOTICE: “ValuEngine Lowers Endologix (ELGX) to Strong Sell” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/valuengine-lowers-endologix-elgx-to-strong-sell/1793105.html.
Endologix Company Profile
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with Analyst Ratings Network's FREE daily email newsletter.